Tags

Type your tag names separated by a space and hit enter

[Acute mixed lineage leukemia showing resistance to AML and ALL therapy].
Rinsho Ketsueki. 1993 May; 34(5):643-8.RK

Abstract

A 51-year-old female was who admitted complaining of cough and slight fever and lower limb petechia. The laboratory examinations revealed leukocytosis (49,400/microliters) with blasts (71%) in the peripheral blood. The NCC was 30 x 10(4)/microliters with 84.8% blasts in the bone marrow. Myeloperoxidase staining was positive for 6% of blasts. Auer rods were not seen in some blasts. Thus, acute myeloblastic leukemia (M1) was diagnosed according to FAB classification. In the peripheral blood, 43.3% of blasts expressed CD19, 10.3% of blasts expressed CD20 and 55.6% of blasts expressed CD33 on admission. Though she received two courses of DCMP according to the DCMP-85 protocol, and one combined course of mitoxantrone, etoposide, and Ara-C. The NCC was 20.0 x 10(4)/microliters with 70% blasts in the bone marrow. CD19 was expressed by 72.4% of blasts and 35.0% expressed CD20. The ALL-90 protocol was started, but remission was not achieved. Thus this case was considered to be acute mixed lineage leukemia.

Authors+Show Affiliations

Third Department of Internal Medicine, Nihon University School of Medicine.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

jpn

PubMed ID

7686236

Citation

Kawashima, H, et al. "[Acute Mixed Lineage Leukemia Showing Resistance to AML and ALL Therapy]." [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, vol. 34, no. 5, 1993, pp. 643-8.
Kawashima H, Iizuka Y, Kondou W, et al. [Acute mixed lineage leukemia showing resistance to AML and ALL therapy]. Rinsho Ketsueki. 1993;34(5):643-8.
Kawashima, H., Iizuka, Y., Kondou, W., Hirota, H., Okuyama, Y., Kanou, M., Ichii, S., Murakami, J., Tsuchiya, T., & Sawada, T. (1993). [Acute mixed lineage leukemia showing resistance to AML and ALL therapy]. [Rinsho Ketsueki] the Japanese Journal of Clinical Hematology, 34(5), 643-8.
Kawashima H, et al. [Acute Mixed Lineage Leukemia Showing Resistance to AML and ALL Therapy]. Rinsho Ketsueki. 1993;34(5):643-8. PubMed PMID: 7686236.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Acute mixed lineage leukemia showing resistance to AML and ALL therapy]. A1 - Kawashima,H, AU - Iizuka,Y, AU - Kondou,W, AU - Hirota,H, AU - Okuyama,Y, AU - Kanou,M, AU - Ichii,S, AU - Murakami,J, AU - Tsuchiya,T, AU - Sawada,T, PY - 1993/5/1/pubmed PY - 1993/5/1/medline PY - 1993/5/1/entrez SP - 643 EP - 8 JF - [Rinsho ketsueki] The Japanese journal of clinical hematology JO - Rinsho Ketsueki VL - 34 IS - 5 N2 - A 51-year-old female was who admitted complaining of cough and slight fever and lower limb petechia. The laboratory examinations revealed leukocytosis (49,400/microliters) with blasts (71%) in the peripheral blood. The NCC was 30 x 10(4)/microliters with 84.8% blasts in the bone marrow. Myeloperoxidase staining was positive for 6% of blasts. Auer rods were not seen in some blasts. Thus, acute myeloblastic leukemia (M1) was diagnosed according to FAB classification. In the peripheral blood, 43.3% of blasts expressed CD19, 10.3% of blasts expressed CD20 and 55.6% of blasts expressed CD33 on admission. Though she received two courses of DCMP according to the DCMP-85 protocol, and one combined course of mitoxantrone, etoposide, and Ara-C. The NCC was 20.0 x 10(4)/microliters with 70% blasts in the bone marrow. CD19 was expressed by 72.4% of blasts and 35.0% expressed CD20. The ALL-90 protocol was started, but remission was not achieved. Thus this case was considered to be acute mixed lineage leukemia. SN - 0485-1439 UR - https://www.unboundmedicine.com/medline/citation/7686236/[Acute_mixed_lineage_leukemia_showing_resistance_to_AML_and_ALL_therapy]_ DB - PRIME DP - Unbound Medicine ER -